All News
EULAR 2021 – Day 1 Report
After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations. Here are a few of the highlights that I saw.
Read Article
OP0186 #EULAR2021 by Dr. Mariele Gatto.
Anti-cancer effect of immunotherapy with ICI is believed to be mediated by CD8 positive Tc cells.
It is not known if other cells get activated. This study looks at B cells.
Transitional B cells ⬆️ in ICI induced arthritis (CP-IA).
/TK https://t.co/szFF81SKVL
ARD & RMD Open ARD_BMJ ( View Tweet)

No requirement to stop cDMARDs before surgery. For biologics stop 1 dose before and restart 14 days post op, JAKi stop 7 days before, restart 14 days post op, glucocorticoids >10mg/day increases risk of infection in #rheumatoidarthritis Michael D George #EULAR2021
Dr. Antoni Chan synovialjoints ( View Tweet)

#POS0093 Collaborative registry studies are to be encouraged! BUT
@k_lauper outlines the heterogenity between registries concerning #AE reporting - Jak-pot study - 18 registries with #RA patients on #tofacitinib - Rates of discontinuation vary across registry
#EULAR2021 @RheumNow https://t.co/oczJAG8hzv
Paul Studenic Stiddyo ( View Tweet)

SPACING trial OP0138 at #EULAR2021
⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo)
⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx
⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Immune events with #checkpointinhibitors 🧐which are the most common? Interesting talk by Maria Suarez-Almazor at #EULAR2021 @eular_org https://t.co/PFPPL4cqOG
EMEUNET EMEUNET ( View Tweet)

You put a pt on a #Jaki What is most likely infection that will occur? #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)

So how do irAEs work?
Dr. Anne Bass @lovetolearn27 @HSpecialSurgery gives #EULAR2021 a possible conceptual framework
@LCalabreseDO @CCalabreseDO @cappelliMD @got_rheum @MarieKostine and so many other good people! @RheumNow https://t.co/5eOZDwkGO6
David Liew drdavidliew ( View Tweet)

An original way of differentiating RA from PsA!
The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of
-HC 94%
-RA 84%
-PsA 89%
and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310
Aurelie Najm AurelieRheumo ( View Tweet)

Presentation 3480 at #EULAR2021. Your patient is on CellCept, has negative COVID spike IgG and IgM antibodies after vaccination with mRNA vaccination x2. What do you counsel on this test? @RheumNow
Eric Dein ejdein1 ( View Tweet)

Anifrolumab pooled TULIP-1&-2 data on rash and arthritis in SLE more effective in pts with high IFN signals (pts with low IFN may benefit, but they had less rash but more arthritis)- Dr. J Merrill #OP0131 #EULAR2021 @rheumnow
k dao KDAO2011 ( View Tweet)

@KDAO2011 @RheumNow @LupusDocLim @Lupusdoc1 @LupusMD Check this! (top left corner)
#HCQ #Lupus #EULAR2021
Link: https://t.co/RQcWoStJtP https://t.co/96l1FvYDQH
Laurent ARNAUD Lupusreference ( View Tweet)

⬆️prevalence of HCQ retinopathy: Kaiser Permanente 676 pts retrospect study #OP0133
👉6.8% (n=46) had HCQ retinopathy w/ risks:
👉age>80 (OR 3.83)
👉h/o atherosclerosis (OR 2.99),
👉cum. dose >2000 mg (OR 15.8)
👉10-15 yrs use (OR 4.44)
👉>15 yrs (OR 19)
#EULAR2021 @rheumnow https://t.co/QA8HHXdnjL
k dao KDAO2011 ( View Tweet)

News: Featured Abstracts from Industry at EULAR 2021
https://t.co/hIBYUdHTLf https://t.co/LTTJ3WPl7X
Links:
Dr. John Cush RheumNow ( View Tweet)

#EULAR Presentation 3478: Infection risk with surgeries:
⭐️Continue conventional DMARD
⭐️Some risk with biologics, may be confounder and no association with timing of infusions
⭐️Steroids are major risk factor! Esp >10 mg/d
⭐️Recommendations shown
⭐️Address other risks!
@rheumnow https://t.co/Bi02d4p9Mw
Eric Dein ejdein1 ( View Tweet)

COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #EULAR2021 poster #POS0912 @RheumNow https://t.co/W2YoyA4K14 https://t.co/lv0GLU2WTF
Links:
Dr. Rachel Tate uptoTate ( View Tweet)

#EULAR2021: Great talk by Dr. McFarland recapping the evidence for managing fibromyalgia.
➡️Over a 6 month time period, costs were significantly lower for people receiving psychological therapies compared to those receiving usual care as shown by Cabral et al. @RheumNow https://t.co/RAkUSeNESy
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow
Eric Dein ejdein1 ( View Tweet)

What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Prednisone are Impt. Piling up risk factors is often multiplied! Biggest risk of serious infection and is recurrent serious infection! #EULAR2021 Meet the expert AbbVie session @RheumNow https://t.co/6m0OfsNF1W
Janet Pope Janetbirdope ( View Tweet)

Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & research from 5 centers in Berlin, 104 PsA pts. Let's get more studies to better understand the power of this measure. Poster #POS1069 #EULAR2021 @RheumNow https://t.co/X4UWGwH5i5 https://t.co/J7EpOjTjhe
Dr. Rachel Tate uptoTate ( View Tweet)